Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.

The conversation discusses hair regrowth using 2-deoxy-d-ribose (2DDR) combined with minoxidil, with some users noting new hair growth. The original poster has been using minoxidil for 12 years and is considering combining 2DDR with finasteride, despite past side effects.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

A 29-year-old male has been using topical finasteride (0.1%) and minoxidil (5%) for 2.5 months and noticed thicker, darker hair. He is considering whether to switch treatments, as the current regimen seems effective.

A user shared progress pictures after 5 months of using 1mg finasteride daily, 1ml minoxidil topically every night, and 1.5mm microneedling weekly. Responses included skepticism and congratulations.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

GHK-Cu is discussed for its potential anti-aging and healing properties, with some users considering its effects on hair growth. One user mentions using Folligen Spray and topical finasteride, noting improved healing but uncertain hair growth results.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.

The user is using a hair recovery treatment with 0.5 mg dutasteride, 5 mg biotin, 5% topical minoxidil, and dermarolling twice a week. They are considering using a 1.5 mm dermaroller and red light therapy.

A 23-year-old male taking 0.25 mg finasteride for 40 days noticed reduced hair shedding and improved hair texture but experienced watery semen, which might be temporary. Overejaculation and finasteride can cause this, and it usually resolves, but consulting a healthcare provider is advised if it persists.

The user achieved significant hair regrowth in 2.5 months using 2.5mg oral minoxidil, 1mg finasteride, weekly microneedling, and ketoconazole shampoo. Microneedling with a derma stamp was particularly effective, and the user also uses topical minoxidil at night.

The user maintained their hair using daily 1mg finasteride, topical minoxidil, vitamins, and a derma roller every 15-20 days. Suggestions included switching to dutasteride and oral minoxidil.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

User reports 2-month progress using Fin, Min, and microneedling for hair regrowth. Mixed opinions on results, some skeptical of fast growth, others encouraging and recommending Fin for stable results.

A user shared their 2-month progress using 1mg finasteride daily, 5% minoxidil with 0.1% finasteride topically twice a day, and Vitamin D3 weekly. They experienced initial side effects like weaker erections and mood swings, which resolved after one month.

User has been using 1.25 mg finasteride and 2.5 mg minoxidil daily for 5 months, along with 5000 mcg biotin for 1.5 months. They noticed peach fuzz growth around month 4 and are seeking confirmation if this indicates hair regrowth.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

Hair loss progress discussed, treatments used include oils, scalp massages, serenoa pills, and dermastamp. User asks for advice without mentioning minoxidil or finasteride.

A user shared their 1.5-year experience using 0.25mg finasteride daily for hair loss, noting significant hair quality improvements and reduced scalp itch but mild erectile dysfunction. They managed side effects with daily 2.5mg Cialis and 5mg citrulline and plan to continue this routine.

User shared progress pictures after 2.5 months of using minoxidil twice daily on eyebrows and temples, along with dermarolling 1-2 times weekly with a 1.5 mm roller. They discussed noticeable improvements in hair growth.